The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

Roivant Sciences Ltd (ROIV) showcases strong financials and strategic advancements while navigating ongoing litigation and competitive pressures.

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

A teenage girl presented to the hospital emergency department with a three-week history of intermittent frontal headache, which was worse in the morning and associated with nausea, vomiting, lethargy, ...

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Researchers conducted a study to characterize ophthalmic adverse events associated with cosmetics and personal care products ...

Vitamin D is crucial for bone health and the immune system, but excessive supplementation can lead to toxicity, causing ...